New drug combo offers hope for bladder cancer patients who failed standard treatment
NCT ID NCT06388720
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 21 times
Summary
This study tests a two-drug combination (mitomycin-C and gemcitabine) given directly into the bladder for people with high-risk non-muscle invasive bladder cancer that did not respond to BCG therapy. The goal is to see if this treatment can prevent the cancer from coming back or getting worse. About 82 adults will take part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center
RECRUITINGGoyang-si, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.